Inoviq Ltd (ASX: IIQ) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Inoviq Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $63.96 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 105.52 million
Earnings per share -0.071
Dividend per share N/A
Year To Date Return -13.53%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Inoviq Ltd (ASX: IIQ)
    Latest News

    Female scientist working in laboratory for Race Oncology
    Healthcare Shares

    What's going on with the Inoviq (ASX:IIQ) share price today?

    The company is set to finish the week on a high note.

    Read more »

    A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused
    Healthcare Shares

    Why has the BARD1 (ASX:BD1) share price vanished from the ASX boards?

    Where are BARD1's shares hiding?

    Read more »

    Vanadium Resources share price person riding rocket indicating share price increase
    Share Gainers

    BARD1 (ASX:BD1) share price ends stellar day up 41%

    BARD1 had a fantastic day...

    Read more »

    Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
    Healthcare Shares

    BARD1 Life Sciences (ASX:BD1) share price leaps 16% on US patent news

    The company's shares are set to finish the week on a positive note.

    Read more »

    man jumping along increasing bar graph signifying jump in alumina share price
    Share Market News

    BARD1 Life Sciences (ASX:BD1) share price jumps on cancer test update

    The quest for BARD1's ELISA test takes another step forward.

    Read more »

    Healthcare Shares

    Here's why the BARD1 (ASX:BD1) share price is falling 7% today

    The market is responding poorly to BARD1's fourth-quarter activities

    Read more »

    share price dropping
    Share Fallers

    Why BARD1, Imugene, Northern Star, & Silver Lake shares are sinking

    It hasn't been a good day for these ASX shares...

    Read more »

    laboratory workers looking disappointed
    Capital Raising

    BARD1 (ASX:BD1) share price falls 6% on placement update

    The medical diagnostics company has secured the first part of its equity raise...

    Read more »

    A dollar sign embedded in ice, indicating a share price freeze or trading halt
    Share Market News

    Here's why the BARD1 (ASX:BD1) share price is frozen today

    All eyes are on BARD1 Life Sciences' halted shares.

    Read more »

    A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
    Healthcare Shares

    Why the BARD1 (ASX:BD1) share price is surging 10% higher

    This healthcare share is on fire today...

    Read more »

    A businessman holds his glasses in concern, indicating uncertainly in the ASX share price
    Share Fallers

    Why the BARD1 (ASX:BD1) share price plummeted 9% today

    The BARD1 Life Sciences Ltd share price has sunk 9% despite announcing a positive update. We take a closer look…

    Read more »

    three excited doctors with hands in the air
    Healthcare Shares

    Here's why the BARD1 (ASX:BD1) share price is crushing it today

    The BARD1 Life Sciences Ltd (ASX: BD1) share price is flying higher today after the company presented data for its…

    Read more »

    IIQ ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Inoviq Ltd

    Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers.

    IIQ Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    16 Jul 2024 $0.57 $-0.01 -1.74% 10,953 $0.57 $0.57 $0.57
    15 Jul 2024 $0.58 $-0.01 -1.72% 91,932 $0.58 $0.58 $0.56
    12 Jul 2024 $0.58 $0.02 3.54% 68,388 $0.57 $0.58 $0.56
    11 Jul 2024 $0.57 $-0.02 -3.42% 38,414 $0.58 $0.58 $0.57
    10 Jul 2024 $0.59 $0.02 3.54% 51,526 $0.57 $0.61 $0.57
    09 Jul 2024 $0.57 $-0.01 -1.75% 138,288 $0.56 $0.60 $0.56
    08 Jul 2024 $0.57 $-0.06 -9.60% 73,404 $0.62 $0.62 $0.57
    05 Jul 2024 $0.63 $0.05 8.70% 196,738 $0.58 $0.63 $0.58
    04 Jul 2024 $0.58 $0.04 7.55% 63,719 $0.54 $0.58 $0.54
    03 Jul 2024 $0.53 $-0.02 -3.64% 141,011 $0.55 $0.55 $0.53
    02 Jul 2024 $0.55 $-0.01 -1.79% 46,077 $0.56 $0.56 $0.55
    01 Jul 2024 $0.56 $0.00 0.00% 60,964 $0.56 $0.57 $0.55
    28 Jun 2024 $0.56 $-0.01 -1.75% 176,319 $0.57 $0.57 $0.54
    27 Jun 2024 $0.57 $0.01 1.80% 111,352 $0.58 $0.58 $0.57
    26 Jun 2024 $0.56 $-0.01 -1.75% 230,612 $0.57 $0.58 $0.55
    25 Jun 2024 $0.57 $0.01 1.79% 69,296 $0.57 $0.58 $0.56
    24 Jun 2024 $0.56 $-0.01 -1.74% 72,964 $0.58 $0.58 $0.56
    21 Jun 2024 $0.58 $0.00 0.00% 74,122 $0.57 $0.59 $0.57
    20 Jun 2024 $0.58 $-0.01 -1.72% 161,464 $0.59 $0.59 $0.57
    19 Jun 2024 $0.58 $-0.06 -9.38% 327,543 $0.65 $0.65 $0.58
    18 Jun 2024 $0.64 $0.02 3.23% 195,197 $0.62 $0.64 $0.61

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr David Williams Non-Executive ChairmanNon-Executive Director Nov 2023
    Mr Philip (Phil) John Powell Non-Executive Director Jun 2019
    Mr Powell has experience in investment banking, specialising in capital raisings, initial public offerings (IPOs), mergers and acquisitions and other corporate finance assignments across a diverse range of sectors including pharma, utilities, IT, financial services, food, and agriculture. He spent 10 years in senior financial roles at OAMPS Ltd, a former ASX-listed financial services group, and 10 years in audit with Arthur Andersen & Co in Melbourne, Sydney, and Los Angeles.
    Mr Geoffrey A. Cumming Non-Executive ChairmanNon-Executive Director Jul 2020
    Dr Cumming has held senior roles in the global healthcare and biotechnology sector for more than 20 years. As Managing Director, Roche Diagnostic Systems (Oceania), Dr Cumming transformed the loss-making entity the Swiss parent was intending to divest, into the growing and profitable affiliate in the Roche group. In his role as Managing Director/CEO of Biosceptre International Ltd, Dr Cumming was in designing and securing key funding arrangements through a range of capital raising initiatives, including government grants, partnering and co-development deals. He is Member of Risk Committee.
    Mr Robert (Max) Maxwell Johnston Non-Executive Director Jun 2019
    Mr Johnston held the position of President and Chief Executive Officer of Johnson & Johnson Pacific, a division of the medical, pharmaceutical and consumer healthcare company for 11 years. Prior to joining Johnson & Johnson, Mr Johnston's career also included senior roles with Diageo and Unilever in Australia, Africa, and Europe. Mr Johnston has also held several industry roles as a past President of ACCORD Australasia Limited, a former Vice Chairman of the Australian Food and Grocery Council and a former member of the board of the Australian Self Medication Industry (ASMI). Mr Johnston has had extensive overseas experience during his career in leading businesses in both Western and Central-Eastern Europe and Africa as well as the Asia-Pacific region. He is Member of Risk Committee.
    Dr Leearne Hinch Chief Executive Officer Nov 2016
    Mr Mark Edwards Chief Financial OfficerCompany Secretary Nov 2022
    Leearne Hinch Chief Executive Officer
    Mark Edwards Chief Financial OfficerCompany Secretary
    Dr Gregory Rice Chief Scientific Officer

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    The Trust Company Australia Limited <Mof A/C> 6,457,000 7.02%
    Dr Irmgard Irminger Finger 3,445,829 3.74%
    Lawn Views Pty Ltd <Angela Williams Family A/C> 2,676,924 2.91%
    The Trust Company (Australia) Limited <Mbf A/C> 2,248,333 2.44%
    Moggs Creek Pty Ltd <Moggs Creek Super A/C> 2,209,747 2.40%
    Lesamourai Pty Ltd 2,000,000 2.17%
    BNP Paribas Nominees Pty Ltd <IB AU NOMS Retailclient DRP> 1,956,453 2.13%
    J P Morgan Nominees Australia Pty Limited 1,508,353 1.64%
    Mr Peter William Rogers & Ms Alida Johanna Clark <R&C Super Fund A/C> 1,217,245 1.32%
    Traoj Pty Ltd <Traoj A/C> 1,102,933 1.20%
    Supergun Pty Ltd <Bricklanding Super Fund A/C> 1,030,000 1.12%
    Mr Nathan Ryan Wagner 1,010,562 1.10%
    Mr Adam Garrigan 1,000,000 1.09%
    David Neate 902,257 0.98%
    Trovex Pty Ltd 820,000 0.89%
    Dr Russell Kay Hancock 750,000 0.82%
    Citicorp Nominees Pty Limited 717,669 0.78%
    B & M Laws Super Fund Pty Ltd <B & M Laws Super Fund A/C> 600,000 0.65%
    Ll&P Pty Ltd <The Andrew Solomons S/F A/C> 584,095 0.63%
    P R Perry Nominees Pty Ltd <Donesk Family A/C> 561,000 0.61%